Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseTalha Munir, Peter Hillmen, Andy C. Rawstron et al.|New England Journal of Medicine|2023Cited by 155
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic LeukemiaTalha Munir, Peter Hillmen, Andy C. Rawstron et al.|New England Journal of Medicine|2025Cited by 26
Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib ExposureAndy C. Rawstron, Peter Hillmen, Sophie Cramp et al.|Blood|2018Cited by 7
Acquired Bruton's tyrosine kinase mutations in patients treated on the ibrutinib and rituximab, ibrutinib alone, and ibrutinib and venetoclax arms of the national multi-centre Phase III FLAIR study in previously untreated CLL patientsCharlotte Evans, Talha Munir, Andy C. Rawstron et al.|Blood|2025Cited by 2